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ABSTRACT 
Brain metastases are common and devastating complications of both breast cancer and 
melanoma. Although mammary carcinoma brain metastases are more frequent than those 
originating from melanoma, this latter has the highest tropism to the brain. Using static and 
dynamic in vitro approaches, here we show that melanoma cells have increased adhesion to the 
brain endothelium in comparison to breast cancer cells. Moreover, melanoma cells can 
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transmigrate more rapidly and in a higher number through brain endothelial monolayers than 
breast cancer cells. In addition, melanoma cells have increased ability to impair tight junctions of 
cerebral endothelial cells. We also show that inhibition of Rac or PI3K impedes adhesion of 
breast cancer cells and melanoma cells to the brain endothelium. In addition, inhibition of Rac or 
PI3K inhibits the late phase of transmigration of breast cancer cells and the early phase of 
transmigration of melanoma cells. On the other hand, the Rac inhibitor EHT1864 impairs the 
junctional integrity of the brain endothelium, while the PI3K inhibitor LY294002 has no 
damaging effect on interendothelial junctions. We suggest that targeting the PI3K/Akt pathway 
may represent a novel opportunity in preventing the formation of brain metastases of melanoma 
and breast cancer. 
Keywords: breast cancer, melanoma, brain metastasis, blood-brain barrier, cerebral endothelial 
cell, adhesion, transmigration, Rac, PI3K 
List of abbreviations: 
BBB   blood-brain barrier 
CEC   cerebral endothelial cell 
CNS   central nervous system 
D3 (hCMEC/D3) human cerebral microvascular endothelial cells, clone D3 
GEF   guanine nucleotide exchange factor 
PI3K   phosphoinositide 3-kinase 
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RBEC   rat brain endothelial cell 
ROCK   Rho-kinase  
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INTRODUCTION 
 
Brain metastases – which are usually late, but devastating complications of cancer – most 
frequently originate from lung cancer, breast cancer and melanoma. Tumor cells successfully 
infiltrating the brain parenchyma overcome several obstacles, including survival in the 
circulation, 
1
 extravasation through brain capillaries (reviewed in: 
2
) and resisting deleterious 
signals of the reactive brain stroma. 
3
 However, cancer cells able to migrate into and to survive in 
the brain will benefit of a supportive and protective microenvironment, including the dense 
vasculature with the opportunity of vessel co-option 
4
 and chemoprotection mediated by 
astrocytes and endothelial cells. 
5
 As a consequence, brain metastases have a poor prognosis. 
Therefore, inhibiting extravasation of metastatic cells into the brain would be of great clinical 
benefit. 
Diapedesis of metastatic cells through the capillaries of the brain implies adhesion of tumor cells 
to the luminal surface of cerebral endothelial cells (CECs), followed by a recently described, not 
yet fully characterized step called incorporation into the monolayer, 
6
 and finally the 
transmigration step itself. CECs are interconnected by a continuous layer of tight junctions and 
form the blood-brain barrier (BBB). The BBB restricts the free movement of solutes between the 
blood and the central nervous system, and represents an impediment for cellular elements 
(leukocytes and metastatic cells) to reach the brain parenchyma (reviewed in: 
7
). We have 
previously shown that melanoma cells are able to disrupt the tight junctions of CECs making 
possible their transmigration through the brain endothelium. 
8
 It is not understood however, 
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whether breast cancer cells are able to disrupt the tight junctions or migrate preferentially 
transcellularly. In fact, transcellular migration of tumor cells has only been described in case of 
breast cancer cells during intravasation into an in vitro vascular network 
9
 and migration through 
umbilical cord endothelial cells. 
10
 However, to our knowledge, no data on the transmigration 
pathway of breast cancer cells through BBB endothelial cells exist. 
Our previous results indicated that during transmigration through the brain endothelium, 
melanoma cells favor the mesenchymal type of cell movement. 
11
 This is characterized by an 
elongated morphology, increased proteolytic activity and is dependent on Rac activity. 
12
 On the 
other hand, the amoeboid type of tumor cell migration is characterized by rounded morphology 
and extensive RhoA signaling. Tumor cells can switch between these two movement types 
depending on the environment they move in. 
13
 By inhibiting Rho/ROCK signaling, and 
therefore triggering the mesenchymal phenotype, a significant increase in the number of 
melanoma cells migrating through CECs could be induced. 
11
 Here we aimed to compare 
melanoma and breast cancer cells in respect of mesenchymal vs. amoeboid migration through the 
brain endothelium. The question whether tumor cells prefer Rho/ROCK or Rac-dependent 
transendothelial migration is of clinical importance, since inhibitors of both Rho/ROCK (e.g. 
fasudil) and Rac pathways 
14
 are emerging as potential therapeutic agents. 
The Rac pathway has been shown to be regulated by phosphoinositide 3-kinase (PI3K) in breast 
cancer cells. 
15
 Moreover, the PI3K/Akt/mTOR pathway is probably the most important in 
respect of anti-cancer treatment targets. 
16
 It has been shown that dysregulation of the PI3K 
signaling pathway is associated with the development of one-third of human cancers, including 
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breast cancers 
17
 and melanomas. 
18
 Aberrant activation of the PI3K pathway promotes 
carcinogenesis, tumor angiogenesis and resistance to therapies, 
19
 and plays a role in cell motility 
as well. 
20
 
Therefore, the first aim of our study was to compare the adhesion and transmigration properties 
of melanoma and breast cancer cells. The second aim was to understand the role of Rac signaling 
and of amoeboid vs. mesenchymal phenotype in the transmigration of breast cancer cells through 
the BBB. The third aim was to investigate whether PI3K inhibition has an impact on the 
transmigration of tumor cells through the cerebral endothelium during brain metastasis 
formation. 
 
RESULTS 
 
Adhesion and transmigration properties of melanoma and breast cancer cells in vitro 
Since melanoma cells have higher propensity to metastasize to the brain than breast cancer cells, 
we aimed to understand whether there is any difference in the interaction of melanoma cells or 
breast cancer cells with the brain endothelium. 
We first aimed to compare the adhesion properties of melanoma and breast cancer cells to the 
brain endothelium. 90 min after plating the tumor cells upon brain endothelial cells, significantly 
more melanoma cells than breast cancer cells were able to attach to the endothelium (Table 1). 
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Therefore, we wanted to test whether the increased adhesion of melanoma cells in comparison to 
breast cancer cells results in an increased transmigration as well. 
For studying the transmigration properties of melanoma and breast cancer cells in static 
conditions, we used a novel approach based on a time-lapse video setup described in the 
Materials and methods section. This innovative assay developed in our laboratory makes 
possible to follow the fate of each individual cell in time (adhesion, migration, division, etc.). 
This approach eliminates the drawbacks of assays using filter inserts, where cells migrating 
through the endothelial monolayer but not moving through the pores of the filter cannot be 
considered. Moreover, several cell types (including D3 cells) cannot be properly grown on large 
pore-size filters due to the formation of a double monolayer on both sides of the membrane. 
Comparing the transmigration properties of melanoma and breast cancer cells using the static 
transmigration assay, we observed that fewer breast cancer cells than melanoma cells were able 
to migrate through the brain endothelium (Table 2). The difference was significant: 27-28% of 
plated melanoma cells completed the transmigration process, while only 16% of breast cancer 
cells migrated through. 
To confirm our results in physiologically more relevant conditions, we constructed a dynamic 
transmigration model. Brain endothelial cells were cultured in a microfluidic device (Fig. 1A; 
described in details in the Material and methods section) until confluence (Suppl. video 1). After 
reaching confluence, a slow, physiologically relevant flow of the culture medium was initiated 
(300 µl/h, 1-2 dyn/cm
2
) for 24 h. Shear stress induced elongation of endothelial cells (Suppl. Fig. 
1). After injection of MDA-MB-231 or A2058 cells, the flow was re-started with a rate of 100 
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μl/h, phase-contrast images were taken and time-lapse videos were constructed to analyze the 
movements of the tumor cells (Fig. 1B, Suppl. videos 2 and 3). 
In these conditions approximately 50% of breast cancer cells and 42.5% of melanoma cells 
showed no attachment and were washed away by the flow of the culture medium in early stages 
of the experiment (Fig. 1B: white circles, Table 3: no attachment). The percentage of tumor cells 
not washed away from the optical fields studied, but not able to transmigrate in 6 h, was 
significantly more in case of breast cancer cells than in case of melanoma cells (15% vs. 4.5%, 
respectively) (Fig. 1B: black circles, Table 3: no transmigration). Taken together, 53% of 
melanoma and 35% of breast cancer cells transmigrated through the brain endothelial monolayer 
in these conditions. The difference in the transmigration between the two cell types was the most 
pronounced in early time points: 23.5% of the total number of melanoma cells migrated through 
the brain endothelium in the first 20 min, while the percentage of breast cancer cells 
transmigrating in this time frame was only 3% (Fig. 1B: white arrows, Table 3: transmigr. in 20 
min). Melanoma cells tended to attach and transmigrate in small groups (Fig. 1B: grey dotted 
star), as we have previously observed in static conditions. 
8
 After transmigration, several 
melanoma cells continued to move beneath and between endothelial cells (as previously seen in 
static conditions 
8
), sometimes rounding up and flattening again (Fig. 1B: cells 1 and 2). A few 
divisions were also observed (Fig. 1B: black boxes) and the daughter cells usually transmigrated 
rapidly after division (Fig. 1B: cell 3). 
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Taken together, these results show that melanoma cells are able to adhere to and migrate through 
the brain endothelium more effectively than breast cancer cells. This might be partly responsible 
for the higher propensity of melanoma cells to metastasize to the brain. 
 
Differences in the effects of melanoma cells and breast cancer cells on the tight junctions of 
brain endothelial cells 
We have previously observed that during transmigration melanoma cells are able to disrupt the 
tight junctions of cerebral endothelial cells and use (at least partly) the paracellular way of 
migration. 
8
 We were interested to understand whether breast cancer cells are also able to impair 
the junctional integrity of the cerebral endothelium. Therefore, we performed claudin-5 
immunostaining on primary rat brain endothelial cell (RBEC) monolayers challenged either with 
MDA-MB-231 breast cancer or with A2058 melanoma cells. As shown on Fig. 2, melanoma 
cells could breach the junctions of RBECs as indicated by focal loss of claudin-5 staining. This 
was not observed in case of breast cancer cells. 
These data suggest that differences in the transendothelial migration of mammary carcinoma and 
melanoma cells might be partly due to differences in their ability to impair interendothelial 
junctions. 
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Inhibition of Rac or PI3K hampers the adhesion of breast cancer cells and melanoma cells 
to the brain endothelium 
We have previously shown that inhibition of the Rho/ROCK pathway facilitates the adhesion of 
melanoma cells, and this effect is reversed by the Rac inhibitor EHT1864. 
11
 We now aimed to 
understand whether the same mechanism applies for breast cancer cells during adhesion to 
cerebral endothelial cells. In contrast to melanoma cells, ROCK inhibitors (10 µM Y27632 or 10 
µM fasudil) were not able to increase the number of breast cancer cells adherent to the brain 
endothelium (Fig. 3A). On the other hand, the Rac inhibitor EHT1864 (20 µM) hampered the 
adhesion of both MDA-MB-231 and MCF-7 breast cancer cells (Fig. 3A and B). As expected, 
mainly the number of elongated adherent cells was decreased, which have a mesenchymal 
phenotype. When both ROCK and Rac inhibitors were applied, a similar reduction in the 
adhesion of tumor cells was seen as with the Rac inhibitor alone (Fig. 3A). In addition, the PI3K 
inhibitor LY294002 in a concentration of 25 µM significantly reduced the number of breast 
cancer and melanoma cells attaching to the brain endothelium. The reduction was approximately 
40% compared to control in case of both breast cancer and melanoma cells, and mainly affected 
tumor cells with elongated (flattened, mesenchymal) phenotype (Fig. 3A-C). In case of A375 
melanoma cells, which presented a rounded morphology during adhesion, LY294002 could also 
significantly reduce the number of adherent cells (Fig. 3D). 
Interestingly, when measuring the adhesion forces using atomic force microscopy between 
MDA-MB-231 breast cancer and hCMEC/D3 brain endothelial cells, or A2058 melanoma and 
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hCMEC/D3 brain endothelial cells, respectively, we could not observe any decrease in response 
to EHT1864 or LY294002 (Suppl. Fig. 2). 
 
Inhibition of Rac or PI3K impedes the transmigration of breast cancer cells and melanoma 
cells through the brain endothelium in static conditions 
Since inhibition of Rac or PI3K decreased the adhesion of both melanoma and breast cancer 
cells, we tested the effect of Rac or PI3K inhibitors on the transmigration of melanoma and 
breast cancer cells through brain endothelial monolayers as well (Fig. 4). In this assay we used 
two invasive melanoma cell lines (A2058 and A375) and the MDA-MB-231 breast cancer cell 
line, which is more invasive than the MCF-7 cell line. Inhibition of Rac with EHT1864 
significantly reduced the transmigration of both tumor cell types to approximately 20% in case of 
breast cancer cells (Fig. 4A) and to 15% in case of melanoma cells (Fig. 4C). LY294002 had 
similar effects: the transmigration percentage was approximately 30% and 40%, respectively, 
compared to control (Fig. 4B, D, E). 
 
Inhibition of Rac or PI3K inhibits the late phase of transmigration of breast cancer cells 
and the early phase of transmigration of melanoma cells through the brain endothelium in 
dynamic conditions 
Using our dynamic model, we explored which step of transmigration of breast cancer or 
melanoma cells was inhibited by EHT1864 or LY294002. As previously discussed (Table 3), 
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only 8% of total transmigrating breast cancer cells completed transmigration in the first 20 min 
(2.8% of 35%), while this was significantly higher in case of melanoma cells (44.34%, i.e. 23.5% 
of 53%). This suggests that melanoma cells can transmigrate more rapidly through the brain 
endothelium than breast cancer cells (Fig. 5). Nevertheless, EHT1864 and LY294002 inhibited 
the rapid transmigration of melanoma cells. However, in case of breast cancer cells the number 
of cells transmigrating after 20 min was reduced by inhibitors of Rac and PI3K (Fig. 5). 
Taken together, our results indicate that inhibition of Rac or PI3K impairs the ability of both 
breast cancer and melanoma cells to adhere to and to migrate through the brain endothelium. 
Differences exist however, between the velocities of the transmigration of the two tumor cell 
types. 
 
Effects of Rac and PI3K inhibitors on the viability, proliferation and migration of tumor 
cells and brain endothelial cells 
We wanted to exclude that the inhibitory effect of EHT1864 and LY294002 on the adhesion and 
transmigration of breast cancer and melanoma cells was due to toxicity on tumor cells. Using the 
EZ4U assay no toxic effect of either EHT1864 or LY294002 on A2058, MDA-MB-231 and 
MCF-7 cells was observed (not shown). Moreover, the EZ4U assay did not show any toxicity of 
EHT1864 or LY294002 on D3 brain endothelial cells. In addition, as assessed during the time-
lapse video experiments, the number of dividing cells was approximately 2.5% in case of MDA-
MB-231 cells and 1% in case of A2058 cells. Therefore, the observed changes in the adhesion 
and transmigration are unlikely to be the result of an anti-proliferative effect of EHT1864 or 
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LY294002. Moreover, the wound healing assay indicated no change in the migratory properties 
of melanoma or breast cancer cells in response to EHT1864 or LY294002 (not shown). 
 
The Rac inhibitor EHT1864 impairs the junctional integrity of the brain endothelium 
We observed that EHT1864 induced a decrease in the impedance of D3 cells, as reflected by the 
cell index on Fig. 6A. After an initial drop induced by the medium change, the impedance of 
control and LY294002-treated D3 cells recovered rapidly. However, in case of EHT1864-treated 
cells the recovery was not complete, and after 5 h a significant drop in the impedance was seen. 
The cell impedance reflects changes in the cell number, viability and tightness of the junctions. 
Since no change in the viability of D3 cells was observed using the EZ4U assay, we next 
investigated the possible damaging effect of the Rac inhibitor on the tight junctions. We 
observed a significant down-regulation of claudin-5 protein in D3 cells in response to EHT1864 
(Fig. 6B). LY294002 did not significantly affect the amount of claudin-5 protein in D3 cells. 
 
DISCUSSION 
 
Brain metastases are devastating complications of lung cancer, breast cancer, melanoma and 
other malignancies. Among all solid tumors, melanoma has the highest affinity to the central 
nervous system. This has been explained by the specific brain environment which supports the 
growth of cells of ectodermal origin. 
21, 22
 However, besides soluble and cellular elements of the 
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central nervous system, other factors might also contribute to the neurotropism of melanoma 
cells. 
One of the most important steps in the process of brain metastasis formation is the diapedesis of 
metastatic cells through the barriers of the CNS, mainly the BBB-forming microvascular 
endothelium. The role of the BBB in the formation of cerebral metastases is largely unexplored 
and probably very complex. Being the tightest endothelial barrier in the organism, it hinders the 
transmigration of tumor cells into the brain. On the other hand, unique brain endothelial 
properties might differentially affect the diapedesis of different cancer cell types. 
2
 
Our results indicate that melanoma cells have increased adhesion to the brain endothelium than 
breast cancer cells. In order to exclude the possibility that this is due to differences in the 
invasive and metastatic capacities between the melanoma and breast cancer cell lines used, we 
used two different breast cancer cell lines: the less invasive MCF-7 and the highly migratory and 
metastatic MDA-MB-231. 
14
 We also used two different melanoma cell lines, A2058 and A375, 
both invasive BRAF V600E mutants, having similar propensity to metastasize to different 
organs, 
23
 A2058 being vemurafenib resistant, while A375 vemurafenib sensitive. 
24
 The 
difference between the adhesive properties of melanoma cells and either of the breast cancer cell 
lines was significant. Moreover, such a difference was not observed when other endothelial cell 
types (HUVECs, dermal microvascular cells, lymphatic endothelial cells) were used: melanoma 
cells had similar adhesion properties to non-cerebral endothelial cells as breast cancer cells. 
25
 
On the other hand, incorporation of A375 into HUVECs was shown to be faster than that of 
MDA-MB-321. 
6
 We have also observed a significant difference in the number of transmigrating 
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melanoma and breast cancer cells. The number of cells not able to migrate through the brain 
endothelium was much higher in case of breast cancer cells than in case of melanoma cells. 
Moreover, invasive melanoma cells tended to complete the transmigration process much more 
rapidly than invasive breast cancer cells. These data suggest that tumor cells with higher affinity 
to the brain can more easily overcome the BBB; however, further studies are needed to support 
this hypothesis. 
Differences between the ability of the two tumor cell types to migrate through the brain 
endothelium might be partly due to their different ability to impair the tight junctions. Our data 
indicate that melanoma cells are more effective in breaking down the paracellular barrier than 
breast cancer cells. Breast cancer cells were previously shown to be able to use not only the 
paracellular pathway (through interendothelial junctions), but also the transcellular pathway 
(through the endothelial cell body) during migration through non-cerebral endothelia. 
9, 10
 Our 
results suggest that breast cancer cells might be more effective in the transcellular type of 
migration than melanoma cells, these latter having increased ability to impair the tight junctions 
than mammary carcinoma cells. Further analyses will clarify this possible difference between the 
two tumor cell types. 
We have also assessed the role of two signaling molecules (Rac and PI3K) in the transmigration 
of melanoma and breast cancer cells through the BBB. In a recent study we showed that 
melanoma cells prefer the Rac-dependent mesenchymal type of cell movement to the 
Rho/ROCK-dependent amoeboid one during transmigration through the BBB. 
11
 Here we show 
that inhibition of Rac not only impedes the adhesion and transmigration of melanoma cells, but 
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of breast cancer cells as well. According to our previous results, ROCK inhibition induced an 
increase in the adhesion force between melanoma and brain endothelial cells. We hypothesized 
that mesenchymal cell flattening was partly responsible for this phenomenon. 
11
 We suppose that 
induction of the amoeboid phenotype using the Rac inhibitor does not have such a significant 
impact on the shape of tumor cells detached from the surface. Therefore, the area of contact 
between tumor cells and endothelial cells does not significantly differ between control and Rac-
inhibited tumor cells, resulting in similar adhesion forces in the presence or absence of 
EHT1864, as measured by AFM. 
Interestingly, the ROCK inhibitors Y27632 or fasudil – which significantly facilitated the 
adhesion of melanoma cells 
11
 – did not affect the adhesive properties of breast cancer cells. 
However, the effect of Rac inhibition was similar in case of both melanoma and breast cancer 
cells: a significant decrease in the number of tumor cells attaching to and transmigrating through 
cerebral endothelial cells was observed. This supports the idea that inhibition of the 
mesenchymal movement of tumor cells might be beneficial in reducing the diapedesis of 
different metastatic cells through the BBB. Unfortunately, Rac inhibitors – in contrast to ROCK 
inhibitors, which prevent the disruption of the tight junctions of CECs – might impair the 
integrity of the BBB. 
Besides Rac, we tested the role of the PI3K/Akt/PTEN pathway, which is a key regulator of 
tumorigenesis and metastasis formation. BRAF-mutant melanoma cells have been shown to have 
higher levels of pAkt-Ser473, pAkt-Thr308 and decreased expression of PTEN. 
26
 The A2058 
cell line used in our experiments is a V600E BRAF mutant expressing high amounts of 
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phosphorylated Akt and low levels of PTEN. 
27
 It has been shown that inhibition of PI3K results 
in a reduction of melanoma cell transmigration through HUVECs. 
28
 Since brain metastases of 
melanoma have been shown to have significantly higher pAkt and lower PTEN levels than 
extracerebral metastases, 
26, 29
 we aimed to test whether inhibition of this pathway impedes the 
transmigration of melanoma cells through CECs. We observed a marked inhibition of melanoma 
cells able to attach to and to migrate through the brain endothelium in response to PI3K 
inhibition. This is in contrast with small cell lung cancer cells, which were not affected by PI3K 
inhibition in their transmigration through brain microvascular endothelial cells. 
30
 It has been 
previously shown that inhibition of Rac or PI3K, but of ROCK also reduces the pulmonary 
microvascular endothelial cell-induced invasiveness of MDA-MB-231 with high α5β1 integrin 
expression. 
31
 According to our results, breast cancer cell transendothelial migration could be 
partly blocked using the PI3K inhibitor LY294002 – similarly to melanoma cells. 
The morphology of PI3K-inhibited tumor cells was similar to that of Rac-inhibited cells, i.e. we 
could see a reduction in the number of elongated, flattened cells. This suggests that PI3K 
inhibition – similar to Rac inhibition – induces an amoeboid-like phenotype in both melanoma 
and breast cancer cells. This is not surprising because PI3K has been shown to regulate Rac 
through P-Rex1 in breast cancer cells 
15
 and several PI3K lipid products have been shown to 
interact with different RacGEFs. 
32
 
In contrast to EHT1864, the PI3K inhibitor LY294002 did not affect the integrity of the BBB. 
Moreover, many PI3K inhibiting agents are in different phases of clinical trials for the treatment 
of different cancer types. 
33
 Based on our results, PI3K inhibitors might turn out to have clinical 
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benefits not only in the treatment of primary tumors, but also in preventing brain metastasis 
formation of breast cancer and melanoma cells. 
In conclusion, we have shown that invasive melanoma cells have an increased capacity to attach 
to, to migrate through and to impair the tight junctions of the brain endothelium than breast 
cancer cells. In addition, inhibition of Rac or PI3K decreases the number of both melanoma and 
breast cancer cells able to transmigrate through cerebral endothelial cells; however, Rac 
inhibition (but not PI3K inhibition) impairs the junctional integrity of the blood-brain barrier. 
Since inhibitors of the PI3K/Akt pathways are emerging as candidates for anti-cancer therapy, 
the mechanism described here might be of clinical relevance. 
 
MATERIALS AND METHODS 
 
Cell culture and treatments 
MDA-MB-231 and MCF-7 human breast cancer cells were kept in DMEM medium (Sigma) 
supplemented with 5% FBS (Lonza). A2058 human melanoma cells (obtained from the 
European Collection of Cell Cultures) were maintained in EMEM (Sigma) supplemented with 
5% FBS (Sigma). A375 human melanoma cells were kept in DMEM medium (Sigma) 
supplemented with 10% FBS (Lonza). The hCMEC/D3 human microvascular cerebral 
endothelial cells (abbreviated as D3) were grown on rat tail collagen-coated dishes in EBM-2 
medium (Lonza) supplemented with EGM-2 Bullet Kit (Lonza) and 2.5% FBS (Sigma). Rat 
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brain endothelial cells (RBECs) used for immunofluorescence experiments were isolated and 
cultured as described previously. 
34
 
ROCK inhibitors (Y27632, Tocris and fasudil, Santa Cruz) were used in a final concentration of 
10 μM. EHT1864 (Tocris), an inhibitor of Rac family GTPases, was applied in a 20 µM 
concentration. LY294002 (Cell Signaling Technology) – a reversible and highly selective 
inhibitor of phosphatidylinositol 3 kinase (PI3K) – was used in a concentration of 25 µM. 
 
Adhesion experiments 
Brain endothelial cells (D3) were grown until confluence in 24-well plates. Tumor cells (MDA-
MB-231, MCF-7 or A2058 cells) were fluorescently labeled using Oregon Green 488 carboxylic 
acid diacetate succinimidyl ester or Cell Tracker red (Life Technologies) using the protocol 
supplied by the manufacturer. 5*10
4
 tumor cells/well were plated onto the endothelial monolayer 
in serum-free medium and incubated for 90 min. Non-attached cells were washed and the 
remaining cells were fixed using ethanol/acetic acid (95/5) at -20°C for 5 min. Tumor cells 
adhered to endothelial cells were photographed and counted using the Image-Pro Plus software 
(Media Cybernetics). 
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Adhesion force measurements 
Single cell force spectroscopy measurement of adhesion forces between tumor cells and 
endothelial cells using atomic force microscopy (AFM) was performed as previously described 
in details. 
11
 
 
Static transmigration experiments using time-lapse video imaging 
Human cerebral endothelial cells (D3) were cultured until confluence in 12-well plates. 
2*10
4
/well tumor cells were plated onto the endothelial monolayer in Leibovitz’s L-15 medium 
(Sigma). Cells were monitored for 6 h using an Andor NEO sCMOS camera connected to a 
Nikon Eclipse Ti-E inverted microscope, equipped with a home built incubator set to 37°C. 
Phase-contrast images were made every 5 min from 5 optical fields/well and time-lapse videos 
were constructed. The movement of each tumor cell was evaluated and transmigrated cells were 
counted. 
 
Dynamic transmigration experiments using microfluidics 
Design and fabrication of microdevices 
To investigate the transmigration of tumor cells under low shear stress conditions we designed 
and constructed a biocompatible artificial capillary network. The schematic representation of the 
microfluidic setup is shown in Fig. 1A. The microfluidic capillary device was fabricated from 
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poly-dimethylsiloxane (PDMS, Sylgard 184, Dow Corning Corp.) using standard 
photolithography and soft lithography techniques. 
35
 Imprints of the microdevices were built by 
creating 100 µm high SU8-2050 negative photoresist (MicroChem Corp.) layers on silicon 
wafers. The photoresist layers were exposed to UV light through a chromium mask (JD Photo-
Tools Ltd.), using a flood exposure source with mask aligner (500W Hg lamp, i-line, model 
97435, Newport Corp. & Digital Exposure Controller model 68945, Newport Corp.). In order to 
prevent the attachment of PDMS to the SU8 molds, the molds were treated with tridecafluoro-
1,1,2,2-tetrahydrooctyl-trichlorosilane (Gelest Inc.) under vacuum overnight. Positive replicas 
were fabricated by PDMS molding. The PDMS replicas were cured, inlet holes and bubble traps 
were punched and the devices were bound to PDMS-covered microscope glass slides using 
oxygen plasma treatment. 
Cell seeding and microfluidic cell culture 
Prior to seeding of brain endothelial cells, the inner surface of the channels was coated with rat 
tail collagen. 10
6
 D3 cells were collected in 100 μl Leibovitz’s L-15 media completed with 2.5% 
FBS (Sigma), growth factor mix (Lonza), hydrocortisone and gentamicin-amphotericin-B and 
injected into the microchannels. The microfluidic devices were placed in a home built incubator 
installed on a microscope stage set to 37°C. Cells were kept in “static conditions” for 24-36 h to 
reach a confluent layer. During this static state the D3 medium was refreshed every 8 h. When 
the confluent endothelial layer fully developed, a continuous flow at 300 μl/h rate was started 
and maintained for 24 h to mimic the blood circulation. 
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During the transmigration experiments 3*10
5
 tumor cells were collected in 100 μl media and 
injected manually (with syringe). After the injection, a continuous flow with 100 μl/h rate was 
established and maintained for 6 h. Considering the physical parameters of the device (channel 
height of ~100 μm, channel width of ~240-480 μm) and the used fluid flow rates (100-300 μl/h), 
we can estimate the shear stress (based on 
36
) acting on the endothelial cells in the 
microchannels. The applied fluid flow generated a low stress regime in our device, in which the 
shear stress was around ~0.3-2 dyn/cm
2
. 
Microscopy 
Phase contrast microscopy images were taken during the cell culturing and the transmigration 
experiments, using an Andor NEO sCMOS camera and a Nikon Eclipse Ti-E microscope (Nikon 
Inc.), equipped with a 20× Plan Fluor phase contrast objectives and a Proscan II motorized 
microscope stage (Prior Scientific Ltd.). We used the Nikon NIS Elements AR software (Nikon 
Inc.) to control the microscope setup during the recordings. Microscopy images were taken every 
30 min during the endothelial cell attachment phase and every 5 min during the transmigration 
experiments (representative images are shown on Fig. 1B). 
Image analysis 
We followed each individual tumor cell in 6 fields/microchannel. Total number of cells counted 
was considered 100% in case of each microchannel. Cells were classified in one of the following 
groups: “no attachment” (cells washed away by the flow of the culture medium in early stages of 
the experiment), “no transmigration” (cells remaining attached to the endothelial layer but not 
able to transmigrate in 6 h), “transmigr. in 20 min” or “transmigr. in >20 min”. Comparison was 
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performed among the four groups in case of each cell type and each treatment, among control 
and EHT1864- or LY294002-treated breast cancer or melanoma cells and among breast cancer 
and melanoma cells. Statistical analysis was performed using ANOVA and Bonferroni’s post-
hoc test. 
 
Immunofluorescence 
RBECs were cultured until confluence on collagen/fibronectin-coated filter inserts. Tumor cells 
(MDA-MB-231 or A2058) were fluorescently labeled using Cell Tracker red (Life 
Technologies) and plated onto the endothelial monolayer. After 5 h cells were washed and fixed 
with ethanol/acetic acid. After blocking with 3% BSA, coverslips were incubated with anti-
claudin-5 primary antibody (Life Technologies). The staining was visualized using a Alexa488-
conjugated secondary antibody. Nuclei were stained with Hoechst 33342. Samples were 
mounted in FluoroMount-G (SouthernBiotech) and studied with a Nikon Eclipse TE2000U 
microscope connected to a digital camera (Spot RT KE, Diagnostic Instruments). 
 
Cell viability assay 
Viability of tumor cells and endothelial cells was quantified with the EZ4U non-radioactive cell 
proliferation and cytotoxicity assay (Biomedica). D3, MDA-MB-231 and MCF-7 cells were 
seeded in 96-well plates. Next day the cells were treated for 5 h with 20 μM EHT1864 or 25 μM 
LY294002 in serum-free, phenol-red free DMEM. After incubation with EZ4U substrate for 45 
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min, the absorbance (OD at 450 nm) was detected using a BMG FLUOstar OPTIMA microplate 
reader. 
 
Wound healing assay 
Tumor cells (MDA-MB-231, MCF-7 or A2058) were seeded into 24-well plates. After 
attachment the cell layer was wounded by scratching with a pipette tip, washed with PBS, and 
exposed to treatments with 20 μM EHT1864 or 25 μM LY294002 in serum-free Leibovitz’s L-
15 medium. Cells were monitored over 24 h, and phase contrast images were taken every 30 min 
with an Andor NEO sCMOS camera connected to the Nikon Eclipse Ti-E inverted microscope 
equipped with a home-built incubator set to 37°C and a 20× Nikon Plan Fluor objective, all 
placed onto a Prior Proscan II motorized stage (Prior Scientific Instruments). The wound healing 
effect was quantified by averaging the number of migrating cells counted in five wounded areas. 
 
Real-time impedance monitoring 
To monitor the effects of EHT1864 and LY294002 on D3 cells in real-time, we measured the 
electrical impedance using the xCELLigence system following the manufacturer’s instructions 
(Acea Biosciences Inc.). Briefly, cells were seeded at a density of 10
4
 cells/well into 100 μl of 
media in an E-Plate® (i.e., 96-well tissue culture plates having micro-electrodes integrated on 
the bottom) and allowed to attach onto the electrode surface over time. The electrical impedance 
was recorded every 15 min. When the impedance reached plateau (i.e. confluent monolayer with 
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well-formed junctions), the cells were treated with 20 μM EHT1864 or 25 μM LY294002 for an 
additional 10 h. The cell impedance (which depends on cell number, degree of adhesion, 
spreading and proliferation of the cells and also the tightness of the junctions), expressed in 
arbitrary units (cell index) was automatically calculated by the software of the instrument. 
 
Western-blot analysis 
Confluent D3 brain endothelial cells were treated with 20 μM EHT1864 or 25 μM LY294002 for 
5 h. Cells were washed with PBS and scraped into ice-cold RIPA buffer (20 mM Tris, 150 mM 
NaCl, 0.5% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 1 mM 
sodium vanadate, 10 mM NaF, 1 mM EDTA, 1 mM Pefabloc) and incubated on ice for 30 min. 
Lysates were clarified by centrifugation at 10,000 g for 10 min at 4°C. Proteins were 
electrophoresed and blotted onto nitrocellulose (Bio-Rad) membranes. Blocking was carried out 
at room temperature for 30 min in TBS-T containing 3% BSA. Anti-claudin-5 (Invitrogen), 
primary antibody was used. After washing the membranes in TBS-T, blots were incubated with 
the HRP-conjugated secondary antibody diluted in TBS-T. The immunoreaction was visualized 
using Clarity ECL Western Blot Substrate kit (Bio-Rad) in a Bio-Rad ChemiDoc MP Imaging 
System. 
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Table 1. Comparison of the adhesion of MDA-MB-231, MCF-7, A2058 and A375 cells to D3 
brain endothelial monolayers. % of plated cells is represented (mean and SD); p value was 
assessed using ANOVA and Bonferroni’s post-hoc test. 
 
  
Table 1
D3+MDA-MB-231 D3+MCF-7 D3+A2058 D3+A375
average 18.44% 18.15% 34.64% 35.05%
st dev 8.66% 8.92% 7.41% 0.75%
p <0.05 vs. A2058 or A375 <0.05 vs. A2058 or A375 <0.05 vs. MDA or MCF <0.05 vs. MDA or MCF
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sz
eg
ed
], 
[Im
ola
 W
ilh
elm
] a
t 0
5:5
3 1
0 D
ec
em
be
r 2
01
5 
  33 
 
Table 2. Comparison of transmigration of MDA-MB-231, A2058 and A375 cells through 
D3 brain endothelial monolayers under static conditions. % of plated cells is represented 
(mean and SD); p value was assessed using Student’s test. 
 
  
Table 2
D3+MDA-MB-231 D3+A2058 D3+A375
average 15.78% 26.99% 28.28%
st dev 0.82% 2.54% 4.72%
p <0.05 vs. A2058 or A375 <0.05 vs. MDA-MB-231 <0.05 vs. MDA-MB-231
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Table 3. Comparison of transmigration of A2058 and MDA-MB-231 cells through D3 brain 
endothelial monolayers under dynamic conditions. MDA-MB-231 breast cancer cells or 
A2058 melanoma cells were injected into the microchannels already containing confluent D3 
monolayers. Tumor cells were monitored for 6 h under a continuous medium flow of 100 μl/h. 
Tumor cells were divided into four groups: cells washed away by the flow of the culture medium 
(no attachment), cells not transmigrating in 6 h (no transmigration), cells migrating through the 
brain endothelium in the first 20 min (transmigr. in 20 min) and cells transmigrating after 20 min 
(transmigr. in >20 min). % of plated cells is represented (mean and SD); p value (comparing 
D3+MDA-MB-231 and D3+A2058) was assessed with ANOVA and Bonferroni’s post-hoc test. 
 
 
  
Table 3
no attachment no transmigration transmigr. in 20 min transmigr. in >20 min
average 50.00% 15.00% 2.80% 32.20%
st dev 4.24% 4.04% 1.73% 3.54%
no attachment no transmigration transmigr. in 20 min transmigr. in >20 min
average 42.50% 4.50% 23.50% 29.50%
st dev 7.21% 1.00% 4.95% 5.12%
p <0.05 <0.05
D3+MDA-MB-231
D3+A2058
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Fig. 1. Dynamic transmigration experimental setup. A: Schematic representation of the 
microfluidic device. B: Images used for constructing the time lapse videos (presented in Suppl. 
videos 2 and 3). D3 cells were cultured until confluence in the microfluidic device, then tumor 
cells were injected and left under a continuous flow of 100 µl/h for 6 h. Phase contrast images 
were taken every 5 min. Individual tumor cells were marked as follows: white circle = no 
attachment, black circle = no transmigration, white arrow = transmigration in 20 min, black 
arrow = transmigration in >20 min, black box = division. The grey dotted stars delineate clusters 
of transmigrating melanoma cells. 
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Fig. 2. Effect of breast cancer and melanoma cells on the tight junctions of brain 
endothelial cells. MDA-MB-231 breast cancer cells or A2058 melanoma cells labeled in red 
were plated onto confluent RBEC monolayers and left for 5 h. Tight junctions of endothelial 
cells were stained in green using anti-claudin-5 antibodies. Arrows indicate disappearance of 
claudin-5 staining. 
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Fig. 3. Effect of Rac- or PI3K-inhibition on the adhesion of breast cancer cells or melanoma 
cells onto the brain endothelium. Fluorescently labeled MDA-MB-231 (A), MCF-7 breast 
cancer cells (B), A2058 (C) or A375 melanoma cells (D) were plated onto confluent D3 
monolayers and left for 90 min. After washing of non-adherent cells, attached tumor cells were 
counted. Results are expressed as % control and given as mean ± SD. N = 3, ** = P<0.01, as 
assessed by ANOVA and Bonferroni’s post-hoc test. 
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Fig. 4. Effect of Rac- or PI3K-inhibition on the transmigration of breast cancer cells or 
melanoma cells through the brain endothelium in static conditions. MDA-MB-231 breast 
cancer cells (A, B), A2058 (C, D) or A375 melanoma cells (E) were plated onto confluent D3 
monolayers and left for 6 h. Phase-contrast images were made every 5 min and transmigrating 
tumor cells were counted. Results are expressed as % control and given as mean ± SD. N = 3, ** 
= P<0.01, * = P<0.05 as assessed by Student’s t-test. 
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Fig. 5. Effect of Rac- or PI3K-inhibition on the transmigration of breast cancer cells or 
melanoma cells through the brain endothelium in dynamic conditions. Results are expressed 
as % control and given as mean ± SD. N = 3, * = P<0.05 EHT1864- or LY294002-treated cells 
compared to control, # = P<0.05 A2058 cells compared to MDA-MB-231 cells, as assessed by 
ANOVA and Bonferroni’s post-hoc test. 
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Fig. 6. Effect of the Rac inhibitor EHT1864 on the junctional integrity of the brain 
endothelium. A: The impedance of D3 brain endothelial cells (represented by the cell index) 
was assessed by the ACEA xCELLigence system. Results are expressed as % control and given 
as mean ± SD. N = 3, * = P<0.05 compared to control, as assessed by ANOVA and Bonferroni’s 
post-hoc test. B: D3 cells were treated with 20 μM EHT1864 or 25 μM LY294002 for 5 h. 
Claudin-5 western-blot was performed from the RIPA-soluble fraction. One representative blot 
and densitometry based on three independent experiments is shown. * = P<0.05 compared to 
control, as assessed by ANOVA and Bonferroni’s post-hoc test. 
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